Trial Profile

A phase II study of Istaroxime for Acute Heart Failure in patients with low systolic blood pressure (SBP) and those who are diuretic resistant

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 02 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Oct 2021 According to a Windtree Therapeutics media release, the company will also include as secondary endpoints, assessments that could potentially become primary pivotal endpoints in the Phase 3 program and thus put the program in what the company believes will be a good Phase 3 ready and partnership position.
25 Oct 2021 According to a Windtree Therapeutics media release, company plans to start the next acute heart failure study by mid-2022 and look to optimize istaroxime dosing by employing a longer infusion duration.
20 May 2020 According to a Windtree Therapeutics media release, the company has received net proceeds which will be used for the study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com